Ausgabe 12/2011
Special issue: L-Dopa-associated motor complications
Inhalt (7 Artikel)
Mechanisms underlying and medical management of l-Dopa-associated motor complications
Manfred Gerlach, Peter Riederer, Dieter Scheller
Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation
Mahmoud M. Iravani, Peter Jenner
Continuous drug delivery in early- and late-stage Parkinson’s disease as a strategy for avoiding dyskinesia induction and expression
P. Jenner, A. C. McCreary, D. K. A. Scheller
Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on l-DOPA-induced dyskinesia
Andrzej Dekundy, Andreas Gravius, Mirko Hechenberger, Małgorzata Pietraszek, Jens Nagel, Carsten Tober, Martine van der Elst, Flora Mela, Christopher G. Parsons, Wojciech Danysz
Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats
E. Grünblatt, W. J. Schmidt, D. K. A. Scheller, P. Riederer, M. Gerlach
Flibanserin attenuates l-DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson’s disease
Manfred Gerlach, Jürgen Beck, Peter Riederer, Maarten van den Buuse
Role of dopamine D3 and serotonin 5-HT1A receptors in l-DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson’s disease
Manfred Gerlach, Gerd D. Bartoszyk, Peter Riederer, Olivia Dean, Maarten van den Buuse